Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
This phase 2 single-arm study aims to demonstrate the efficacy of strong cytochrome
inhibition with ketoconazole to reduce dasatinib dosage for adults with chronic myelogenous
leukemia. Researchers will describe response rates and adverse events.